Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

AbbVie (ABBV) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareABBV

Latest price · Nov 20, 2026 $288.62 +1.8% on the day · +28.8% over 12 months 52-week range $195.99 – $295.03
Get ABBV alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling4last 12 months
Reported sales$30.8M4 of 7 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
Latest open-market trade

Sale Jeffrey Ryan Stewart, Evp, Chief Commercial Officer sold 40,619 shares at $293.60 ($11.9M).

Trade date
Nov 9, 2026
Disclosed to the SEC
Nov 12, 2026
Type
Sale (code S)

Read the original SEC filing ↗All ABBV insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

ABBV insider transactions (Form 4)

Open-market purchases and sales. 64 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 12SEC Jeffrey Ryan StewartEvp, Chief Commercial Officer Sell 40,61983,171 held (−33%) $293.60 $11.9M -1.7% —
Aug 18SEC Nicholas DonoghoeEvp, Chief Bus/Strat Officer Sell 32,71074,430 held (−31%) $250.00 $8.2M +15.4% —
Mar 6SEC David Ryan PurdueSvp, Controller Sell 5,2302,654 held (−66%) $233.56 $1.2M +23.6% —
Mar 3SEC Perry C. SiatisEvp, Gc And Secretary Sell Plan 10,2917,219 held (−59%) $234.66 $2.4M +23.0% —
Mar 3SEC Perry C. SiatisEvp, Gc And Secretary Sell Plan 5,77717,510 held (−25%) $233.51 $1.3M +23.6% —
Mar 3SEC Perry C. SiatisEvp, Gc And Secretary Sell Plan 2,6004,619 held (−36%) $235.26 $612K +22.7% —
Feb 27SEC Perry C. SiatisEvp, Gc And Secretary Sell Plan 22,38138,137 held (−37%) $230.00 $5.1M +25.5% —
Historical context

Similar past setups: not applicable. ABBV has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with ABBV in the Research Lab

ABBV has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

ABBV closeInsider buyInsider sale
150200250300DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-07EEarnings release filed 2026-02-04EEarnings release filed 2026-04-03EEarnings release filed 2026-04-29EEarnings release filed 2026-07-06EEarnings release filed 2026-07-31EEarnings release filed 2026-10-05EEarnings release filed 2026-10-30Sold $1,221,519 on 2026-03-04 · David Ryan PurdueSold $4,375,549 on 2026-03-02 · Perry C. SiatisSold $5,147,630 on 2026-02-25 · Perry C. SiatisSold $8,177,500 on 2026-08-14 · Nicholas DonoghoeSold $11,925,738 on 2026-11-09 · Jeffrey Ryan Stewart
Bought, 12 months$0
Sold, 12 months$30.8M
Insiders buying0
Insiders selling4

AbbVie insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 4 sold $30.8M of ABBV stock on the open market; P/E 62.3 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

ABBV insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $10.7M sold (5 trades)Q1 2026Q2 2026Q3 2026: $8.2M sold (1 trades)Q3 2026Q4 2026: $11.9M sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$11.9M1
Q3 2026—0$8.2M1
Q2 2026—0—0
Q1 2026—0$10.7M5

Valuation, profit and volume

P/E (trailing)62.3Sector median 25.0
Volume vs. 50-day0.8×Last 5 sessions

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 AbbVie insiders reported open-market purchases totaling $0, while 4 insiders reported sales totaling $30.8M. 4 of 7 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ABBV earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 30, 2026 +3.2% None -0.7%S&P -2.2% pending
Oct 5, 2026 -0.5% None +1.5%S&P +1.2% +8.7%
Jul 31, 2026 +5.4% None -4.8%S&P +2.2% +6.8%
Jul 6, 2026 +18.0% None -2.5%S&P +0.4% -3.6%
Apr 29, 2026 -3.5% None +6.9%S&P +1.0% +3.0%
Apr 3, 2026 +0.2% Sold $1.2M -1.0%S&P +0.5% +0.0%
Feb 4, 2026 +5.3% None -2.9%S&P -1.7% +5.1%
Jan 7, 2026 -1.7% None +0.1%S&P -0.3% +0.5%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

ABBV short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 49% of volume sold short2026-08-27: 48% of volume sold short2026-08-28: 45% of volume sold short2026-08-31: 52% of volume sold short2026-09-01: 50% of volume sold short2026-09-02: 39% of volume sold short2026-09-03: 50% of volume sold short2026-09-04: 64% of volume sold short2026-09-08: 65% of volume sold short2026-09-09: 48% of volume sold short2026-09-10: 67% of volume sold short2026-09-11: 54% of volume sold short2026-09-14: 65% of volume sold short2026-09-15: 57% of volume sold short2026-09-16: 56% of volume sold short2026-09-17: 59% of volume sold short2026-09-18: 61% of volume sold short2026-09-21: 54% of volume sold short2026-09-22: 39% of volume sold short2026-09-23: 48% of volume sold short2026-09-24: 38% of volume sold short2026-09-25: 38% of volume sold short2026-09-28: 37% of volume sold short2026-09-29: 46% of volume sold short2026-09-30: 46% of volume sold short2026-10-01: 44% of volume sold short2026-10-02: 64% of volume sold short2026-10-05: 51% of volume sold short2026-10-06: 57% of volume sold short2026-10-07: 49% of volume sold short2026-10-08: 52% of volume sold short2026-10-09: 47% of volume sold short2026-10-12: 52% of volume sold short2026-10-13: 41% of volume sold short2026-10-14: 58% of volume sold short2026-10-15: 40% of volume sold short2026-10-16: 18% of volume sold short2026-10-19: 41% of volume sold short2026-10-20: 27% of volume sold short2026-10-21: 27% of volume sold short2026-10-22: 23% of volume sold short2026-10-23: 23% of volume sold short2026-10-26: 30% of volume sold short2026-10-27: 34% of volume sold short2026-10-28: 36% of volume sold short2026-10-29: 32% of volume sold short2026-10-30: 38% of volume sold short2026-11-02: 14% of volume sold short2026-11-03: 17% of volume sold short2026-11-04: 20% of volume sold short2026-11-05: 36% of volume sold short2026-11-06: 47% of volume sold short2026-11-09: 41% of volume sold short2026-11-10: 29% of volume sold short2026-11-11: 27% of volume sold short2026-11-12: 37% of volume sold short2026-11-13: 24% of volume sold short2026-11-16: 35% of volume sold short2026-11-17: 32% of volume sold short2026-11-18: 47% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 47%20-day average: 30%Prior 2 months: 48%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded ABBV

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $15,001 - $50,000 Mar 27, 2026Jul 21, 2026 +40.0%
John BoozmanSenate Sold $1,001 - $15,000 Aug 22, 2025Sep 12, 2025 +41.3%
John BoozmanSenate Sold $1,001 - $15,000 Aug 11, 2025Sep 12, 2025 +49.8%

Insiders at AbbVie

InsiderBoughtSoldLast filingPast buys beat S&PScore
Jeffrey Ryan StewartEvp, Chief Commercial Officer — $11.9M Nov 12, 2026 — —
Perry C. SiatisEvp, Gc And Secretary — $9.5M Mar 3, 2026 — —
Nicholas DonoghoeEvp, Chief Bus/Strat Officer — $8.2M Aug 18, 2026 — —
David Ryan PurdueSvp, Controller — $1.2M Mar 11, 2026 — —
Azita SalekiEvp, Chief Operations Officer — — Nov 18, 2026 — —
Roxanne S. AustinDirector — — May 12, 2026 2 of 2 —
Edward J. RappDirector — — May 12, 2026 1 of 1 —
Thomas J. FalkDirector — — May 12, 2026 — —
Frederick H. WaddellDirector — — May 12, 2026 — —
Thomas C. FreymanDirector — — May 12, 2026 — —
Rebecca B. RobertsDirector — — May 12, 2026 — —
Brett J. HartDirector — — May 12, 2026 — —
William H.L. BurnsideDirector — — May 12, 2026 — —
Melody B. MeyerDirector — — May 12, 2026 — —
Jennifer L. DavisDirector — — May 12, 2026 — —
Susan E. QuagginDirector — — May 12, 2026 — —
Demetris D. CrumEvp, Chief Hr Officer — — Mar 6, 2026 — —
Robert A. MichaelCEO, Chair — — Mar 3, 2026 — —
Scott T. ReentsCFO — — Mar 3, 2026 — —
Roopal ThakkarEvp, R&D And Cso — — Mar 3, 2026 — —

Board links: companies that share insiders with ABBV

Directors and executives who filed Form 4s for ABBV and another company in the last 12 months.

See the map →
  • CRWDCrowdStrike Roxanne S. Austin Director here · Director at CRWD · latest filing Sep 15, 2026
  • PGProcter & Gamble Jennifer L. Davis Director here · CEO at PG · latest filing May 12, 2026
  • UALUnited Airlines Brett J. Hart Director here · President at UAL · latest filing Nov 3, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

ABBV stock: common questions

Are AbbVie insiders buying ABBV stock?

No. No AbbVie insider reported an open-market purchase of ABBV in the past 12 months.

Are AbbVie insiders selling ABBV stock?

4 insiders reported sales worth $30.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ABBV's P/E ratio?

ABBV trades at about 62.3 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is ABBV's 52-week range?

Over the past year ABBV has traded between $195.99 and $295.03. It last closed at $288.62 on Nov 20, 2026.